Top Clinical Trials companies in Germany by Shareholders' Equity
Germany
# |
Name |
Shareholders' Equity |
Reported Date | Stock Price |
Change |
Price (30 days) | Country |
|---|---|---|---|---|---|---|---|
| 1 |
USD 554.91 M
|
Dec. 31, 2023 | USD 56.80 | 2.07% |
|
Germany |
|
| 2 |
USD 550.66 M
|
Dec. 31, 2023 | USD 42.78 | -0.17% |
|
Germany |
|
| 3 |
USD 248.44 M
|
Dec. 31, 2023 | USD 5.47 | 1.30% |
|
Germany |
|
| 4 |
USD 242.96 M
|
Dec. 31, 2023 | USD 1.55 | -3.12% |
|
Germany |
|
| 5 |
USD 113.32 M
|
Dec. 31, 2023 | USD 2.41 | 1.69% |
|
Germany |
|
| 6 |
USD 53.71 M
|
Nov. 30, 2023 | USD 2.46 | -3.82% |
|
Germany |
|
| 7 |
USD 29.01 M
|
Dec. 31, 2023 | USD 2.02 | -0.68% |
|
Germany |
|
| 8 |
USD 3.25 M
|
Dec. 31, 2023 | USD 7.25 | -0.69% |
|
Germany |
Frequently Asked Questions
-
Which Clinical Trials company in Germany has the highest Shareholders' Equity ?
The Clinical Trials company in Germany with the highest Shareholders' Equity is Formycon AG (XETRA: FYB.DE) at USD 554.91 M.
-
Which Clinical Trials company in Germany has the lowest Shareholders' Equity ?
The Clinical Trials company in Germany with the lowest Shareholders' Equity is Mainz Biomed B.V. (NasdaqCM: MYNZ) at USD 3.25 M.
-
What are the top 10 Clinical Trials companies in Germany by Shareholders' Equity ?
The top 10 Clinical Trials companies in Germany by Shareholders' Equity are Formycon AG, Biotest AG, Immatics N.V., Atai Life Sciences N.V., InflaRx N.V., Heidelberg Pharma AG, Vivoryon Therapeutics N.V. and Mainz Biomed B.V..
-
What are the bottom 10 Clinical Trials companies in Germany by Shareholders' Equity ?
The bottom 10 Clinical Trials companies in Germany by Shareholders' Equity are Mainz Biomed B.V., Vivoryon Therapeutics N.V., Heidelberg Pharma AG, InflaRx N.V., Atai Life Sciences N.V., Immatics N.V., Biotest AG and Formycon AG.
